Therapeutic drug monitoring (TDM) is the clinical practice of
determining the concentration of a specific drug in a patient’s
bloodstream at different intervals. Therapeutic drug monitoring (TDM)
helps to sustain a constant volume of drug in bloodstream required to
show therapeutic effects without toxic effects, thereby optimizing
individual dosage regimens. Therapeutic drug monitoring (TDM) is
generally not deployed for majority of drugs, rather it is used
primarily for monitoring drugs with narrow therapeutic window, medicines
for which required concentrations are challenging to monitor, drugs
with marked pharmacokinetic variability, and drugs known to cause
adverse effects. TDM begins with the initiation of medication, and
involves determining a preliminary dosage regimen suitable for the
clinical state and patient characteristics as age, body mass index,
weight, organ function, and associated drug therapy. TDM serves in
assessing the efficiency and safety of a medication when administered
into the individual patient.
The therapeutic drug monitoring (TDM) market is anticipated to
witness healthy growth during the forecast period, owing to steep rise
in the demand for better healthcare for the growing urban population.
Increased knowledge of pharmacogenetics and pharmacokinetics of drugs is
inclining the clinicians towards therapeutic drug monitoring (TDM) of
certain medications. Rapid increase in the prevalence of complex
neurological diseases and cancer have fueled the demand for high end
diagnostic methods such as genetic testing which in turn is anticipated
to boost therapeutic drug monitoring (TDM) market. Moreover, increasing
investments in research and development of novel drugs and vaccines by
private and government bodies is also expected to propel the demand for
the therapeutic drug monitoring (TDM) market in the near future. In
addition, rise in the geriatric population, especially in developing
geographies and development of innovative tools in medication management
are further driving this market. However, low research and development
(R&D) returns, high infrastructure cost, stringent regulatory
framework, and lack of trained resources are some of the restraints of
the therapeutic drug monitoring (TDM) market.
The therapeutic drug monitoring (TDM) market can be segmented on the
basis of product type, technology, drug class, end user and region. The
product type segment can be further segmented into number of equipment
such as immunoassay analyzers, spectrophotometers, chromatograms, and
consumables. Increasing preference for technologically advanced
services, product innovation, and growing number of diseases is
anticipated to fuel the therapeutic drug monitoring (TDM) market growth.
On the basis of technology the market is segmented into immunoassays
such as chemiluminescent assays (CLIA), enzyme-linked immunosorbent
assay (ELISA), proteomics technologies, chromatography, etc. On the
basis of drug class, the market can be segmented into antiepileptics,
antibiotics, psychoactive drugs, antiarrhythmic drugs, bronchodilators,
immunosuppressants, and others.
Geographically, the therapeutic drug monitoring (TDM) market can be segmented into North America, Europe, Asia Pacific, Middle East and Africa and Latin America. North America is estimated to hold the largest share of the global therapeutic drug monitoring (TDM) market due to the presence of superior health care base, strong regional economics, and greater emphasis on prevention and wellness by government. This trend is also reflected in other countries. The therapeutic drug monitoring (TDM) market in Europe is expected to witness rapid growth, attributed to high consciousness about wellbeing in the region coupled with increasing spending on healthcare services. Countries such as China, Japan, and India in the Asia Pacific are poised to be the most promising markets for therapeutic drug monitoring (TDM) in the near future. Major factors for the positive outlook are extensive development of health care infrastructure, and growing emphasis on research and development in the health care sector.
Key players operating in the therapeutic drug monitoring market include Abbott Diagnostics, Danaher Corporation, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Siemens Healthcare, Roche Diagnostics, Thermo Fisher Scientific, and Agilent Technologies.
Report Overview @ https://www.transparencymarketresearch.com/therapeutic-drug-monitoring-market.html
Geographically, the therapeutic drug monitoring (TDM) market can be segmented into North America, Europe, Asia Pacific, Middle East and Africa and Latin America. North America is estimated to hold the largest share of the global therapeutic drug monitoring (TDM) market due to the presence of superior health care base, strong regional economics, and greater emphasis on prevention and wellness by government. This trend is also reflected in other countries. The therapeutic drug monitoring (TDM) market in Europe is expected to witness rapid growth, attributed to high consciousness about wellbeing in the region coupled with increasing spending on healthcare services. Countries such as China, Japan, and India in the Asia Pacific are poised to be the most promising markets for therapeutic drug monitoring (TDM) in the near future. Major factors for the positive outlook are extensive development of health care infrastructure, and growing emphasis on research and development in the health care sector.
Key players operating in the therapeutic drug monitoring market include Abbott Diagnostics, Danaher Corporation, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Siemens Healthcare, Roche Diagnostics, Thermo Fisher Scientific, and Agilent Technologies.
No comments:
Post a Comment